A carregar...
Phase II trial of docetaxel–irinotecan combination in advanced esophageal cancer
Background: Preclinical evidence suggests synergy between docetaxel and irinotecan, two drugs active in esophagogastric cancer. We previously demonstrated the safety of docetaxel 35 mg/m(2) and irinotecan 50 mg/m(2) given on days 1 and 8 of a 21-day schedule. Materials and methods: Patients who had...
Na minha lista:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2009
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2699385/ https://ncbi.nlm.nih.gov/pubmed/19429872 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdn787 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|